Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | MITF | O75030 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | YAP1 | P46937 | 1/20 | 0.30 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365346 | 0.80 | ALDH1A1 (0.52) | ALDH1A1NLRP3LMNAMAPTL3MBTL1 | |
| SCHEMBL1991051 | 0.80 | NLRP3 (0.35) | ALDH1A1NLRP3MAPTL3MBTL1APEX1 | |
| Nibrozetone SCHEMBL2249018 | 0.80 | NLRP3 (0.47) | ALDH1A1NLRP3LMNAMAPTL3MBTL1 | |
| SCHEMBL22015927 | 0.77 | NLRP3 (0.33) | NLRP3MAPTL3MBTL1 | |
| SCHEMBL21626535 | 0.76 | POLB (0.41) | ALDH1A1POLBSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL20547329 | 0.73 | ALDH1A1 (0.50) | ALDH1A1POLBHTTSMN1; SMN2LMNA | |
| SCHEMBL27012291 | 0.73 | ALDH1A1 (0.50) | ALDH1A1POLBHTTSMN1; SMN2LMNA | |
| SCHEMBL14841644 | 0.72 | NLRP3 (0.34) | NLRP3APEX1 | |
| SCHEMBL30787950 | 0.72 | JAK2 (0.31) | NLRP3 | |
| SCHEMBL24414321 | 0.72 | ALDH1A1 (0.48) | ALDH1A1POLBHTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924253-B1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | ALLIANT TECHSYSTEMS INC (US) | 2014-12-10 | — | — | EP | claimed |
| US-7745643-B2 | chemical synthesizing a N-(haloacetyl)-3,3-dinitro-azetidine compound; anticarciogenic, antiinflammatory, antihypoxic, antidiabetic agent; cardiovascular and autoimmune disease; rheumatoid arthritis, diabetic retinopathy | ALLIANT TECHSYSTEMS INC. (US) | 2010-06-29 | — | — | US | claimed |
| US-20090093644-A1 | METHODS OF SYNTHESIZING CYCLIC NITRO COMPOUNDS | ALLIANT TECHSYSTEMS INC. (US) | 2009-04-09 | — | — | US | claimed |
| US-20250049756-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NORTHROP GRUMMAN SYSTEMS CORP (US) | 2025-02-13 | — | — | US | disclosed |
| US-11925617-B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | NORTHROP GRUMMAN SYSTEMS (US) | 2024-03-12 | — | — | US | disclosed |
| US-20220016077-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NORTHROP GRUMMAN INNOVATION SYSTEMS LLC | 2022-01-20 | — | — | US | disclosed |
| US-20200046682-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2020-02-13 | — | — | US | disclosed |
| US-10149832-B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | EPICENTRX, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180085346-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | Northrop Grumman Innovation Systems, Inc. | 2018-03-29 | — | — | US | disclosed |
| US-20160199346-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2016-07-14 | — | — | US | disclosed |
| US-9226915-B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | EPICENTRX, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20130123216-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | ALLIANT TECHSYSTEMS INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8299053-B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | RADIORX, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8178698-B2 | Methods of synthesizing cyclic nitro compounds | ALLIANT TECHSYSTEMS INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110130572-A1 | METHODS OF SYNTHESIZING CYCLIC NITRO COMPOUNDS | ALLIANT TECHSYSTEMS INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7745643-B2 | chemical synthesizing a N-(haloacetyl)-3,3-dinitro-azetidine compound; anticarciogenic, antiinflammatory, antihypoxic, antidiabetic agent; cardiovascular and autoimmune disease; rheumatoid arthritis, diabetic retinopathy | ALLIANT TECHSYSTEMS INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090163466-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | RADIORX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090093644-A1 | METHODS OF SYNTHESIZING CYCLIC NITRO COMPOUNDS | ALLIANT TECHSYSTEMS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7507842-B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | RADIORX, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070135384-A1 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | RADIORX, INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123216-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NOS1, NOS2, NOS3 | ALDH1A1 1432/4885NLRP3 559/4885POLB 943/4885 |
| US-20160199346-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NOS1, NOS2, NOS3 | ALDH1A1 1432/4885NLRP3 559/4885POLB 943/4885 |
| US-20110130572-A1 | METHODS OF SYNTHESIZING CYCLIC NITRO COMPOUNDS | NOS2, NOS1, NOS3 | ALDH1A1 1408/4885NLRP3 965/4885POLB 539/4885 |
| US-20200046682-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NOS1, NOS2, NOS3 | ALDH1A1 1432/4885NLRP3 559/4885POLB 943/4885 |
| US-20090093644-A1 | METHODS OF SYNTHESIZING CYCLIC NITRO COMPOUNDS | NOS2, NOS1, NOS3 | ALDH1A1 1408/4885NLRP3 965/4885POLB 539/4885 |
| US-20180085346-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NOS1, NOS2, NOS3 | ALDH1A1 1432/4885NLRP3 559/4885POLB 943/4885 |
| US-20220016077-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NOS1, NOS2, NOS3 | ALDH1A1 1432/4885NLRP3 559/4885POLB 943/4885 |
| US-10149832-B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | NOS1, NOS2, NOS3 | ALDH1A1 1432/4885NLRP3 559/4885POLB 943/4885 |
| US-20070135384-A1 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | NOS1, NOS2, NOS3 | ALDH1A1 1432/4885NLRP3 559/4885POLB 943/4885 |
| US-11925617-B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | NOS1, NOS2, NOS3 | ALDH1A1 1432/4885NLRP3 559/4885POLB 943/4885 |
| US-20090163466-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NOS1, NOS2, NOS3 | ALDH1A1 1432/4885NLRP3 559/4885POLB 943/4885 |
| US-20250049756-A1 | CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | NOS1, NOS2, NOS3 | ALDH1A1 1432/4885NLRP3 559/4885POLB 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.